查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863448

新抗原癌症疫苗市場（依新抗原類型、治療標靶、疫苗平台、給藥途徑和最終用戶分類）－2025年至2032年全球預測

Neoantigen Cancer Vaccine Market by Neoantigen Type, Therapeutic Target, Vaccine Platform, Administration Route, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，新抗原癌症疫苗市場將成長至 11.9114 億美元，複合年成長率為 15.40%。

關鍵市場統計數據
基準年 2024 3.7866億美元
預計年份：2025年 4.3455億美元
預測年份 2032 11.9114億美元
複合年成長率 (%) 15.40%

對新抗原癌症疫苗的簡要介紹，整合了科學創新、臨床進展和相關人員的策略考量。

新抗原癌症疫苗代表了腫瘤學領域的模式轉移，它利用腫瘤特異性肽特徵來調動適應性免疫對抗惡性腫瘤。新抗原疫苗的核心在於利用獨特或共用的新抗原——由腫瘤特異性突變或復發性腫瘤相關改變產生的抗原決定簇——來精準靶向T細胞反應。定序技術、生物資訊學和合成生物學的進步縮短了從發現到生產的周期，使得從腫瘤切片檢查到候選疫苗的快速轉化成為可能。這種技術融合推動新抗原疫苗從概念可行性階段發展成為涵蓋學術機構、生技公司和臨床聯盟的強大轉化研發管線。

在臨床上，新抗原策略正在單藥治療以及與現有治療方法（例如免疫查核點抑制劑和過繼性細胞療法）聯合治療中進行評估。依證強調了免疫抗原性、安全性以及擴增抗腫瘤T細胞庫的能力。在營運方面，需要涉及基因組學、抗原預測、GMP生產和臨床營運的多學科合作，這既為研發人員及其合作夥伴帶來了機遇，也帶來了挑戰。因此，對於希望將科學進步轉化為持續的臨床和商業性成果的利害關係人相關人員，明確市場區隔、區域動態、供應鏈韌性和商業化路徑等策略至關重要。

對正在重塑下一代新抗原疫苗格局的變革性技術、臨床、生產和監管轉變進行分析綜合，以實現創新。

新抗原疫苗領域正經歷一場變革性的轉變，其驅動力主要來自四個相互關聯的因素：技術成熟、聯合治療的臨床檢驗、不斷發展的供應鏈以及不斷變化的監管要求。技術成熟包括腫瘤定序通量的提高、更先進的表位預測演算法以及新一代RNA和DNA遞送平台的進步，這些進步顯著提升了抗原表現的準確性。這些進步減少了候選疫苗篩選的瓶頸，並使得設計更具免疫抗原性的構建體成為可能。因此，研發人員正在探索創新平台，例如環狀DNA支架和新一代RNA化學技術，以加快迭代速度，並提高疫苗的穩定性和免疫誘導效力。

在臨床方面，將新抗原疫苗與免疫查核點抑制劑聯合應用的研究數據正在推動從純粹的實驗通訊協定轉變為具有明確終點的結構化聯合治療策略。這項臨床進展也推動了生產模式的轉變，分散式和區域化生產模式正在試驗推行，以縮短週轉時間並消除低溫運輸的依賴。法規結構也在進行調整，監管機構日益重視簡化個人化生物製劑的核准途徑，同時強調標準化的療效測試和嚴格的藥物監測。這些變化共同重塑了專案的規劃、資金籌措和患者交付方式，強調模組化、可擴展的方法以及整個生態系統中的策略夥伴關係。

該報告對計劃於2025年實施的美國關稅調整如何影響新抗原疫苗生態系統的供應鏈選擇、製造地和籌資策略進行了客觀評估。

美國已實施或預計2025年實施的關稅政策正對研發新型抗原疫苗的公司的商業決策產生重大影響，尤其因為該產業依賴全球分散的試劑、合成寡核苷酸、脂質奈米顆粒、特殊耗材和生物加工設備等供應基地。對進口試劑和組件徵收更高的關稅可能會增加投入品的到岸成本，並擠壓缺乏採購規模的早期研發企業的利潤空間。為此，許多機構正在調整籌資策略，優先選擇國內或區域供應商，重新談判供應商契約，並加快對替代供應商的合格，以確保關鍵原料的持續供應。

除了對單位成本的影響外，關稅的累積效應正在強化近岸外包和本地生產的策略合理性。研發企業和契約製造製造商正日益權​​衡利用低成本海外生產與接受更長的前置作業時間和關稅風險之間的利弊。同時，關稅也促使人們更加關注供應鏈透明度、庫存計劃和雙重採購，以降低單一來源風險。在政策層面，研發企業正更積極地與產業協會和監管機構溝通，以明確生物製藥及相關材料的關稅分類，並在可能的情況下尋求豁免和關稅減免。總而言之，這些調整正在影響有關設施投資、合作夥伴選擇和專案時間表的決策，但並未改變新抗原疫苗研發的科學基礎。

全面的細分分析以指導策略優先排序：整合新型抗原類型、治療標靶、疫苗平台、給藥途徑和最終用戶

這種細分方法為評估新抗原疫苗的臨床應用、技術選擇和商業化路徑提供了一個實用的框架。根據新抗原的類型，市場分為「個人化新抗原」和「共用新抗原」。個人化新抗原透過免疫逃脫和體細胞突變進行深入分析，而共用新抗原則則著重於親和性肽和通用腫瘤突變進行評估。這種細分方法明確了治療範圍：個人化方法優先考慮根據個別突變譜客製化的抗原庫，而共用策略則針對複發性突變，從而擴大患者適用範圍並實現潛在的現貨供應。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過整合人工智慧驅動的新抗原辨識平台，增強個人化疫苗設計。
  • 採用多重體學技術提高臨床試驗中新型抗原發現的準確性
  • 基於mRNA的新抗原疫苗平台的出現使得快速生產成為可能
  • 生技公司與學術機構合作，加速新抗原的臨床檢驗過程
  • 增加針對黑色素瘤和肺癌的個人化新抗原疫苗計畫的投資
  • 著重研究新抗原疫苗與查核點抑制劑合併應用以提高固態腫瘤的治療效果

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依新抗原類型分類的新抗原癌症疫苗市場

  • 個人化新抗原
    • 免疫逃脫突變
    • 體細胞突變
  • 共用的新抗原
    • 親和性肽
    • 通用腫瘤突變

9. 新抗原癌症疫苗市場依治療標靶分類

  • 免疫查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
  • 腫瘤新抗原
    • 突變新抗原
    • 非突變新抗原

10. 疫苗平台型新抗原癌症疫苗市場

  • 細胞疫苗
    • 樹突細胞疫苗
    • T細胞疫苗
  • DNA疫苗
    • 環狀DNA平台
    • 質體DNA疫苗
  • 基於胜肽的疫苗
    • 長胜肽
    • 合成胜肽
  • 基於RNA的疫苗
    • mRNA疫苗
    • 下一代RNA平台

第11章 新抗原癌症疫苗市場依給藥途徑分類

  • 皮內給藥
  • 靜脈注射
  • 口服
  • 皮下注射

第12章 依最終用戶分類的新抗原癌症疫苗市場

  • 癌症治療中心
  • 醫院
  • 研究所

第13章 各地區新抗原癌症疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 新抗原癌症疫苗市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國新抗原癌症疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Agenus Inc.
    • AstraZeneca PLC
    • Avidea Technologies
    • Ayala Pharmaceuticals, Inc.
    • BioLineRx Ltd.
    • BioNTech SE
    • BioVaxys Technology Corp.
    • Brightpath Biotherapeutics Co., Ltd.
    • CureVac NV
    • Elicio Therapeutics Inc
    • F. Hoffmann-La Roche Ltd.
    • Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
    • Genocea Biosciences Inc
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • Gritstone bio, Inc.
    • Immunomic Therapeutics, Inc.
    • ISA Pharmaceuticals BV
    • Medigene AG
    • Merck & Co., Inc.
    • Moderna, Inc.
    • Neophore Limited
    • Nouscom AG
    • Nykode Therapeutics ASA
    • OSE Immunotherapeutics
    • Takis Srl
Product Code: MRR-5C6F41F5AFED

The Neoantigen Cancer Vaccine Market is projected to grow by USD 1,191.14 million at a CAGR of 15.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 378.66 million
Estimated Year [2025] USD 434.55 million
Forecast Year [2032] USD 1,191.14 million
CAGR (%) 15.40%

A concise introduction to neoantigen cancer vaccines that synthesizes scientific innovation, clinical momentum, and strategic considerations for stakeholders

Neoantigen cancer vaccines represent a paradigm shift in oncology, harnessing tumor-specific peptide signatures to mobilize adaptive immunity against malignancies. At their core, these interventions exploit unique or shared neoantigens-antigenic determinants arising from tumor-specific mutations or recurrent tumor-associated changes-to direct T cell responses with precision. Advances in sequencing, bioinformatics, and synthetic biology have compressed the discovery-to-manufacture timeline, enabling more rapid translation from tumor biopsy to vaccine candidate. This technical convergence has moved neoantigen vaccines from conceptual promise to a robust translational pipeline across academic centers, biotechnology companies, and clinical consortia.

Clinically, neoantigen strategies are being evaluated across monotherapy settings and in combination with established modalities such as immune checkpoint inhibitors and adoptive cell therapies. The evidence base emphasizes immunogenicity, safety, and the capacity to broaden antitumor T cell repertoires. Operationally, the space demands interdisciplinary coordination-genomics, antigen prediction, GMP manufacturing, and clinical operations-creating both opportunities and complexity for developers and their partners. Consequently, strategic clarity around segmentation, regional dynamics, supply chain resilience, and commercialization pathways has become essential for stakeholders aiming to convert scientific advances into durable clinical and commercial outcomes.

An analytical synthesis of the transformative technological, clinical, manufacturing, and regulatory shifts redefining the neoantigen vaccine landscape for the next wave of innovation

The neoantigen vaccine landscape is undergoing transformative shifts driven by four interlocking forces: technological maturation, clinical validation of combination approaches, supply chain evolution, and shifting regulatory expectations. Technological maturation spans improvements in tumor sequencing throughput, enhanced algorithms for epitope prediction, and next-generation RNA and DNA delivery platforms that increase antigen expression fidelity. These advances have reduced bottlenecks in candidate identification while enabling the design of more immunogenic constructs. As a result, developers are iterating faster and exploring innovative platforms such as circular DNA scaffolds and next-gen RNA chemistries to improve stability and immune priming.

Clinically, emerging data from studies that pair neoantigen vaccines with immune checkpoint blockade have catalyzed a move from purely experimental protocols to structured combinatorial strategies with clearer endpoints. This clinical momentum is accompanied by changes in manufacturing paradigms; decentralized and regionalized production models are being piloted to shorten turnaround times and address cold chain dependencies. Regulatory frameworks are also adapting, with agencies increasingly open to streamlined pathways for individualized biologics while emphasizing standardized potency assays and robust pharmacovigilance. Together, these shifts are redefining how programs are designed, financed, and brought to patients, emphasizing modular, scalable approaches and strategic partnerships across the ecosystem.

A pragmatic assessment of how United States tariff adjustments slated for 2025 are shaping supply chain choices, manufacturing footprints, and procurement strategies across the neoantigen vaccine ecosystem

Tariff policies implemented or anticipated by the United States for 2025 have had a material influence on the operational calculus of neoantigen vaccine developers, particularly because the sector relies on an internationally distributed supply base for reagents, synthetic oligonucleotides, lipid nanoparticles, specialized consumables, and bioprocess equipment. Increased duties on imported reagents and components raise the landed cost of inputs and can compress margins for early-stage developers who lack purchasing scale. In response, many organizations have adjusted procurement strategies to prioritize domestic or regional suppliers, renegotiated supplier contracts, and accelerated qualification of alternative sources to maintain continuity of critical raw materials.

Beyond unit cost implications, cumulative tariff effects have reinforced the strategic rationale for nearshoring and regional manufacturing. Developers and contract manufacturers are increasingly evaluating the trade-offs between capitalizing on lower-cost offshore production and accepting longer lead times and tariff exposure. At the same time, tariffs have prompted greater attention to supply chain transparency, inventory planning, and dual-sourcing to mitigate single-source risk. On the policy front, developers are engaging more actively with trade associations and regulators to clarify tariff classifications for biologics and associated materials, seeking exemptions or tariff relief when feasible. Collectively, these adjustments are shaping decision-making around facility investment, partnership selection, and program timelines without altering the fundamental scientific trajectories of neoantigen vaccine development.

Comprehensive segmentation insights that integrate neoantigen types, therapeutic targets, vaccine platforms, administration routes, and end users to guide strategic prioritization

Segmentation offers a pragmatic framework to evaluate clinical applications, technology choices, and commercialization pathways for neoantigen vaccines. Based on neoantigen type, the market is studied across Personalized Neoantigens and Shared Neoantigens; Personalized Neoantigens are further examined through immune escape mutations and somatic mutations, while Shared Neoantigens are assessed with attention to affinity peptides and common tumor mutations. This segmentation clarifies therapeutic scope: personalized approaches prioritize bespoke antigen repertoires tailored to an individual's mutational landscape, whereas shared strategies target recurrent alterations that enable broader patient applicability and potential off-the-shelf offerings.

Based on therapeutic target, the market is studied across Immune Checkpoint Blockade and Tumor Neoantigens; Immune Checkpoint Blockade is further examined across CTLA-4 inhibitors and PD-1 inhibitors, and Tumor Neoantigens are further parsed into mutated neoantigens and non-mutated neoantigens. This axis highlights the importance of combinatorial design and target selection in optimizing immune activation. Based on vaccine platform, the market is studied across Cell-Based Vaccines, DNA-Based Vaccines, Peptide-Based Vaccines, and RNA-Based Vaccines; Cell-Based Vaccines are further examined across dendritic cell vaccines and T-cell vaccines, DNA-Based Vaccines are further explored across circular DNA platforms and plasmid DNA vaccines, Peptide-Based Vaccines are further categorized into long peptides and synthetic peptides, and RNA-Based Vaccines are further evaluated across mRNA vaccines and next-generation RNA platforms. This platform segmentation illuminates trade-offs in manufacturing complexity, antigen expression durability, and dosing strategies. Based on administration route, the market is studied across intradermal, intravenous, oral, and subcutaneous delivery, an axis that affects immunogenicity, patient experience, and clinical logistics. Finally, based on end user, the market is studied across cancer treatment centers, hospitals, and research institutes, underscoring where clinical adoption, trial execution, and translational research investment are concentrated. Together, these segmentation lenses enable strategic prioritization of clinical indications, platform investments, and partner selection to maximize translational and commercial impact.

Key regional dynamics and operational considerations for neoantigen vaccine development across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional dynamics exert a strong influence on R&D intensity, regulatory timelines, manufacturing strategy, and commercial access for neoantigen vaccine programs. In the Americas, an innovation-rich environment with extensive clinical trial networks and significant private capital supports rapid technology translation, though program timelines can be affected by complex payer landscapes and site activation logistics. The United States in particular remains a center for platform innovation and first-in-human studies, while broader North American networks facilitate multi-center studies and public-private collaborations.

In Europe, Middle East & Africa, diverse regulatory jurisdictions and a strong foundation in academic translational research create opportunities for collaborative consortia and harmonized clinical evaluation through centralized regulatory mechanisms. Several countries within the region are advancing clinical infrastructure and adaptive trial frameworks conducive to personalized biologics. Asia-Pacific presents a heterogeneous landscape characterized by fast-growing biotech clusters, government-led incentives for biomanufacturing, and rapidly expanding clinical trial capacity. Emerging markets in the region are increasingly investing in local manufacturing capabilities and regulatory modernization, which can accelerate regional access but also necessitate tailored regulatory and commercialization strategies. Developers must therefore adopt a region-specific approach to partnerships, clinical site selection, and manufacturing footprint planning to align with differing regulatory expectations, reimbursement environments, and patient access pathways.

Strategic competitive landscape analysis highlighting platform leaders, partnership models, and intellectual property dynamics shaping neoantigen vaccine commercialization

The competitive landscape for neoantigen vaccines features a spectrum of organizations, from pioneering biotechs focusing on individualized approaches to larger oncology companies integrating neoantigen platforms into broader immuno-oncology portfolios. Leading developers concentrate on platform robustness-accuracy of antigen prediction, speed of manufacturing, and breadth of antigen presentation-while strategic collaborators provide scale in production, distribution, and late-stage clinical development. Academic centers remain crucial sources of translational innovation, hosting early trials that validate antigen selection methods and combination regimens.

Partnership models are evolving: strategic alliances with contract development and manufacturing organizations accelerate GMP translation; licensing deals with platform owners enable larger firms to access specialized antigen-prediction algorithms; and collaborative networks with clinical consortia expedite multicenter studies. Investment patterns prioritize platforms that can reduce time from sequence to product, support modular manufacturing, and de-risk regulatory pathways through standardized assay development. Intellectual property around epitope selection algorithms, delivery chemistry, and manufacturing processes is a differentiator, influencing strategic positioning and M&A interest as stakeholders seek to integrate vertical capabilities and shorten commercialization timelines.

Actionable recommendations for industry leaders to align platform innovation, regulatory engagement, and supply chain resilience for successful neoantigen vaccine programs

Industry leaders should adopt a multi-pronged strategy that aligns scientific differentiation with operational resilience and market access planning. First, prioritize platform investments that reduce turnaround time from tumor sequencing to vaccine release by integrating advanced prediction algorithms, automated manufacturing workflows, and robust quality control assays. Concurrently, establish flexible manufacturing partnerships and regional supply relationships to mitigate tariff exposures and ensure continuity of critical inputs.

Second, design clinical programs that emphasize strategic combinations with immune checkpoint inhibitors and standardized endpoints that resonate with regulators and payers. Early engagement with regulatory authorities to align on potency assays, safety monitoring frameworks, and evidence-generation plans will streamline later-stage development. Third, pursue modular commercialization strategies that balance personalized and shared neoantigen approaches; leverage shared neoantigen candidates to create scalable offerings while using personalized programs to address high-unmet-need indications. Finally, invest in cross-functional capabilities-data management, regulatory science, and health economics-to articulate value to payers, accelerate reimbursement discussions, and support sustainable adoption pathways.

A transparent and reproducible research methodology integrating primary expert interviews, rigorous secondary analysis, and structured technology assessment frameworks

This research synthesizes primary interviews with clinical investigators, regulatory experts, manufacturing leaders, and commercial strategists, alongside secondary analysis of peer-reviewed literature, clinical trial registries, and public regulatory guidance. Data collection emphasized reproducible methods: interview protocols were standardized to capture program design choices, operational challenges, and strategic priorities, and qualitative responses were triangulated with documented case studies and regulatory filings to ensure accuracy.

Analytical methods combined thematic analysis of qualitative inputs with technology assessment frameworks to evaluate platform readiness, manufacturability, and scalability. Risk assessments focused on supply chain dependencies, regulatory heterogeneity, and clinical development complexity. Comparative profiling of platforms and programs used consistent criteria-development stage, platform maturity, manufacturing complexity, and strategic partnerships-to support clear, comparable insights. Throughout, the methodology prioritized transparency and traceability so that conclusions can be validated against primary sources and updated as new data emerge.

A forward-looking conclusion that synthesizes scientific progress, operational imperatives, and collaborative pathways to advance neoantigen vaccine adoption

Neoantigen cancer vaccines are at an inflection point where scientific maturation and operational innovation are jointly unlocking new therapeutic possibilities. The convergence of improved antigen prediction, diversified delivery platforms, and strategic clinical combinations is creating viable pathways from discovery to patient administration. At the same time, practical challenges-supply chain exposures, regulatory harmonization, and the need for scalable manufacturing-require deliberate strategic responses to translate immunological promise into broadly accessible treatments.

Looking forward, success will favor organizations that combine scientific differentiation with operational discipline: those that can validate antigen selection empirically, demonstrate consistent manufacturing quality, and articulate economic value to payers. Collaborative ecosystems-linking developers, CDMOs, clinical networks, and regulators-will accelerate progress, while region-specific manufacturing and regulatory strategies will shape access. In sum, the field presents compelling opportunities for stakeholders who can integrate translational science with pragmatic execution to bring next-generation neoantigen vaccines into clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven neoantigen identification platforms to enhance personalized vaccine design
  • 5.2. Adoption of multiplexed immunopeptidomics to improve neoantigen discovery accuracy in trials
  • 5.3. Emergence of mRNA-based neoantigen vaccine platforms advancing rapid manufacturing timelines
  • 5.4. Collaboration between biotech and academic centers to accelerate neoantigen clinical validation processes
  • 5.5. Increasing investment in personalized neoantigen vaccine programs targeting melanoma and lung cancer
  • 5.6. Focus on combining neoantigen vaccines with checkpoint inhibitors to boost therapeutic efficacy in solid tumors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 8.1. Personalized Neoantigens
    • 8.1.1. Immune Escape Mutations
    • 8.1.2. Somatic Mutations
  • 8.2. Shared Neoantigens
    • 8.2.1. Affinity Peptides
    • 8.2.2. Common Tumor Mutations

9. Neoantigen Cancer Vaccine Market, by Therapeutic Target

  • 9.1. Immune Checkpoint Blockade
    • 9.1.1. CTLA-4 Inhibitors
    • 9.1.2. PD-1 Inhibitors
  • 9.2. Tumor Neoantigens
    • 9.2.1. Mutated Neoantigens
    • 9.2.2. Non-Mutated Neoantigens

10. Neoantigen Cancer Vaccine Market, by Vaccine Platform

  • 10.1. Cell-Based Vaccines
    • 10.1.1. Dendritic Cell Vaccines
    • 10.1.2. T-Cell Vaccines
  • 10.2. DNA-Based Vaccines
    • 10.2.1. Circular DNA Platforms
    • 10.2.2. Plasmid DNA Vaccines
  • 10.3. Peptide-Based Vaccines
    • 10.3.1. Long Peptides
    • 10.3.2. Synthetic Peptides
  • 10.4. RNA-Based Vaccines
    • 10.4.1. mRNA Vaccines
    • 10.4.2. Next-Gen RNA Platforms

11. Neoantigen Cancer Vaccine Market, by Administration Route

  • 11.1. Intradermal
  • 11.2. Intravenous
  • 11.3. Oral
  • 11.4. Subcutaneous

12. Neoantigen Cancer Vaccine Market, by End User

  • 12.1. Cancer Treatment Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Neoantigen Cancer Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neoantigen Cancer Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neoantigen Cancer Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Agenus Inc.
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Avidea Technologies
    • 16.3.4. Ayala Pharmaceuticals, Inc.
    • 16.3.5. BioLineRx Ltd.
    • 16.3.6. BioNTech SE
    • 16.3.7. BioVaxys Technology Corp.
    • 16.3.8. Brightpath Biotherapeutics Co., Ltd.
    • 16.3.9. CureVac N.V.
    • 16.3.10. Elicio Therapeutics Inc
    • 16.3.11. F. Hoffmann-La Roche Ltd.
    • 16.3.12. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
    • 16.3.13. Genocea Biosciences Inc
    • 16.3.14. GenScript Biotech Corporation
    • 16.3.15. Gilead Sciences, Inc.
    • 16.3.16. Gritstone bio, Inc.
    • 16.3.17. Immunomic Therapeutics, Inc.
    • 16.3.18. ISA Pharmaceuticals B.V.
    • 16.3.19. Medigene AG
    • 16.3.20. Merck & Co., Inc.
    • 16.3.21. Moderna, Inc.
    • 16.3.22. Neophore Limited
    • 16.3.23. Nouscom AG
    • 16.3.24. Nykode Therapeutics ASA
    • 16.3.25. OSE Immunotherapeutics
    • 16.3.26. Takis S.r.l.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY P